EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen iD, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun und 5 weitere

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70166 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Zhuang Kang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glioma, Neoplasm Recurrence, Local, Brain Neoplasms, Receptors, Vascular Endothelial Growth Factor. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Runshi Medical Technology Co. Ltd, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813 , a dual inhibitor of VEGFR and CSF1R , in patients with recurrent high‐grade gliomas.

Methods

Eligible patients (aged ≥ 18) with histologically or cytologically confirmed recurrent high‐grade gliomas were included. Patients were administered different doses of SYHA1813 daily to assess its safety and initial efficacy.

Results

Sixty‐four individuals with high‐grade gliomas were enrolled. Treatment‐related adverse events (TRAEs) were reported in 92.2% of the patients, with 40.6% experiencing grade 3 or higher TRAEs. No grade 5 TRAE was reported. The overall objective response rate (ORR) and disease control rate (DCR) were 18.8% (95% confidence interval [CI], 10.1–30.5) and 51.6% (95% CI, 38.7–64.3), respectively. With a median follow‐up duration of 9.5 months, the median progression‐free survival (PFS) was 2.8 months (95% CI, 2.3–4.2) with PFS‐6 of 22.5% (95% CI, 11.8–35.4) and the median OS was 15.1 months (95% CI, 10.2–NE) with OS‐12 of 63.3% (95% CI, 49.3–74.4). Among the 38 patients with glioblastoma, the ORR was 18.4% (95% CI, 7.7–34.3), with a DCR of 52.6% (95% CI, 35.8–69.0). The median PFS and OS were 4.1 months (95% CI, 2.3–5.3) and 13.0 months (95% CI, 9.1–NE), respectively. SYHA1813 was detected in cerebrospinal fluid samples and the drug concentration to plasma free drug concentration ratio was 0.30–1.27.

Interpretation

SYHA1813 exhibits encouraging anti‐tumor activity with a manageable safety profile for the treatment of recurrent high‐grade gliomas, especially glioblastoma. Trial Registration chictr.org.cn (ChiCTR2100045380)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaNeoplasm Recurrence, LocalBrain NeoplasmsReceptors, Vascular Endothelial Growth FactorReceptors, Granulocyte-Macrophage Colony-Stimulating FactorHumansFemaleMaleMiddle AgedAdultAgedYoung AdultReceptor, Macrophage Colony-Stimulating Factor

Stichwörter der Autor:innen

SYHA1813VEGFR1‐3/CSF1Rglioblastomahigh‐grade gliomasrecurrence

Substanzen

CSF1R protein, humanReceptors, Vascular Endothelial Growth FactorReceptors, Granulocyte-Macrophage Colony-Stimulating FactorReceptor, Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Neurosurgery, Tangdu Hospital, Air Force Military Medical University, Xi'an, China.
  • Department of Neurosurgery, Hubei General Hospital, Renmin Hospital of Wuhan University, Wuhan, China.
  • Department of Oncology, Hubei General Hospital, Renmin Hospital of Wuhan University, Wuhan, China.
  • Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Qianxue Chen, Wenbin Li

Förderung

  • Shanghai Runshi Medical Technology Co. Ltd
  • National Natural Science Foundation of China

Zitieren

APA

Kang, Z., Li, S., Wang, L., Chen, Q., Hu, W., Lei, T., Mao, Y., Zhang, J., Xiang, X., Wang, Q., He, Z., Sun, T., Wang, Y., Huang, M., Zhang, R., Chen, F., & Li, W. (2025). SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70166

Vancouver

Kang Z, Li S, Wang L, Chen Q, Hu W, Lei T, et al. SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70166

BibTeX
@article{Kang2025,
  author = {Kang, Zhuang and Li, Shenglan and Wang, Liang and Chen, Qianxue and Hu, Weiguo and Lei, Ting and Mao, Ying and Zhang, Jing and Xiang, Xiaojun and Wang, Qiming and He, Zhengwen and Sun, Tao and Wang, Yulei and Huang, Mengqian and Zhang, Rong and Chen, Feng and Li, Wenbin},
  title = {SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70166}
}
Kostenlos starten →